Vancomycin (oral)

C. diff Risk


Oral Bioavailability


Approximate Cost


Spectrum Of Activity


125 mg PO q6h X 10-14 days

See IWK Clostridium Difficile Guidelines

General Information

Common Usage

Only indication is in the therapy of C. difficile infection, particularly recurrent or severe disease

Drug Monitoring

Possibility of accumulation in severe renal dysfunction; consider checking a vancomycin level in dialysis patients

Major Interactions

Avoid concurrent administration of oral vancomycin and bile acid sequestrants (may diminish therapeutic effect of vancomycin).

Oral Liquids

Concentration: 25 mg/mL (compounded)
Taste: metallic taste
Not all strengths of oral liquids are listed nor are available on IWK formulary

Tablet/Capsule Strengths

125 mg capsule
Tablets and capsules are preferred especially over an unpleasant tasting liquid.
Not all strengths of oral tablets/capsules are listed and they are not all available on the IWK formulary.

Additional Information

No oral absorption. May increase vancomycin resistant enterococci colonization in the gut


Antimicrobial class: glycopeptide

Average serum half life: serum half life not available due to low systemic absorption

Route of Elimination: Primarily feces as limited absorption